Last reviewed · How we verify

Genovate Biotechnology Co., Ltd., — Portfolio Competitive Intelligence Brief

Genovate Biotechnology Co., Ltd., pipeline: 2 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 1 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Abilify (aripiprazole) Abilify (aripiprazole) marketed Atypical antipsychotic Dopamine D2 receptor (partial agonist), Serotonin 5-HT1A receptor (partial agonist) Psychiatry / Neurology
Combigan Ophthalmic Solutiom Combigan Ophthalmic Solutiom marketed Fixed-dose combination of alpha-2 adrenergic agonist and beta-adrenergic antagonist Alpha-2 adrenergic receptors and beta-adrenergic receptors Ophthalmology
Nidadd Nidadd phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Acacia Pharma Ltd · 1 shared drug class
  2. Alexza Pharmaceuticals, Inc. · 1 shared drug class
  3. Alkermes, Inc. · 1 shared drug class
  4. All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
  5. AstraZeneca · 1 shared drug class
  6. Benaroya Research Institute · 1 shared drug class
  7. BioXcel Therapeutics Inc · 1 shared drug class
  8. AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Genovate Biotechnology Co., Ltd.,:

Cite this brief

Drug Landscape (2026). Genovate Biotechnology Co., Ltd., — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/genovate-biotechnology-co-ltd. Accessed 2026-05-16.

Related